RSLS
ReShape Lifesciences Inc
Price:  
6.05 
USD
Volume:  
65,836
United States | Health Care Equipment & Supplies

RSLS WACC - Weighted Average Cost of Capital

The WACC of ReShape Lifesciences Inc (RSLS) is 8.4%.

The Cost of Equity of ReShape Lifesciences Inc (RSLS) is 8.4%.
The Cost of Debt of ReShape Lifesciences Inc (RSLS) is 5%.

RangeSelected
Cost of equity6.9% - 9.9%8.4%
Tax rate0.4% - 0.5%0.45%
Cost of debt5.0% - 5.0%5%
WACC6.9% - 9.9%8.4%
WACC

RSLS WACC calculation

CategoryLowHigh
Long-term bond rate3.9%4.4%
Equity market risk premium4.6%5.6%
Adjusted beta0.670.9
Additional risk adjustments0.0%0.5%
Cost of equity6.9%9.9%
Tax rate0.4%0.5%
Debt/Equity ratio
0.010.01
Cost of debt5.0%5.0%
After-tax WACC6.9%9.9%
Selected WACC8.4%

RSLS's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for RSLS:

cost_of_equity (8.40%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.67) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.